Sign In
Buy OCX
$3.20
+0 (+0%)
At Close: Sep 16, 2025
4 Stocks Under $5 Insiders Are Aggressively Buying
12:48pm, Monday, 18'th Apr 2022 Benzinga
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the co
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11
Pfizer Inc (
Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants
02:01am, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today the pricing of an underwritten public offering of 26,266
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
09:12pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today that it has commenced an underwritten public offering of
Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
09:10pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company with the mission to improve patient outc
Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
12:00pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Poster outlines data showing Oncocyte’s DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer
Poster outlines data showing Oncocyte's DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer
What 4 Analyst Ratings Have To Say About OncoCyte
02:00pm, Friday, 18'th Mar 2022 Benzinga
OncoCyte (NASDAQ:OCX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
0
Last 30D
0
1
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022
03:03pm, Monday, 14'th Mar 2022 Benzinga
Upgrades
Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in
OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)
09:03am, Friday, 11'th Mar 2022 Zacks Investment Research
OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)
05:17am, Friday, 11'th Mar 2022
OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte Corporation 2021 Q4 - Results - Earnings Call Presentation
04:48am, Friday, 11'th Mar 2022 Seeking Alpha
OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q4 2021 Results - Earnings Call Transcript
04:47am, Friday, 11'th Mar 2022 Seeking AlphaOncoCyte Corporation (OCX) CEO Ronnie Andrews on Q4 2021 Results - Earnings Call Transcript
11:47pm, Thursday, 10'th Mar 2022
OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q4 2021 Results - Earnings Call Transcript
OncoCyte (OCX) Reports Q4 Loss, Lags Revenue Estimates
10:35pm, Thursday, 10'th Mar 2022 Zacks Investment Research
OncoCyte (OCX) delivered earnings and revenue surprises of -20% and 17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
